Kyoung Eun Joung1, Kyung-Hee Park2, Andreas Filippaios3, Fadime Dincer3, Helen Christou4, Christos S Mantzoros5. 1. Division of Newborn Medicine, Boston Children's Hospital, 300 Brookline Ave, Boston, MA, 02115, USA; Department of Pediatrics, Division of Neonatology, Goryeb Children's Hospital, 100 Madison Ave, Morristown, NJ, 07960, USA; Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, 300 Brookline Ave, Boston, MA, 02215, USA; Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA. 2. Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, 300 Brookline Ave, Boston, MA, 02215, USA; Department of Family Medicine, Hallym University Sacred Heart Hospital, Hallym University, Gyeonggi-do, 431-070, Republic of Korea. 3. Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, 300 Brookline Ave, Boston, MA, 02215, USA. 4. Division of Newborn Medicine, Boston Children's Hospital, 300 Brookline Ave, Boston, MA, 02115, USA; Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA; Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA. Electronic address: hchristou@partners.org. 5. Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, 300 Brookline Ave, Boston, MA, 02215, USA; Section of Endocrinology, Division of Endocrinology, Boston VA Healthcare System, Jamaica Plain, MA, 02130, USA; Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA.
Abstract
BACKGROUND: Irisin is a novel myokine, secreted from skeletal muscle after exercise. Irisin mediates exercise-related energy expenditure by turning white adipose tissue (WAT) into brown adipose tissue (BAT). Thus, irisin is considered as a potential biomarker for obesity and metabolic syndrome. Infants born small for gestational age (SGA) have increased risk for metabolic syndrome. However, the physiologic role of irisin in neonates remains to be studied. OBJECTIVE: To evaluate the association of umbilical cord blood irisin levels with gestational age and birth weight categories in neonates. METHODS: A cross-sectional study of 341 newborns, from 26 to 41weeks' gestation. We collected umbilical cord blood and analyzed plasma for irisin by ELISA. RESULTS: Plasma irisin levels were positively correlated with gestational age (r=0.21, p<0.001), and birth weight Z-score (r=0.18, p<0.001). SGA infants had significantly lower irisin (median [interquartile range] 55.38 [46.56-65.72]ng/mL) compared to appropriate for gestational age infants (64.41 [53.87-76.76]ng/mL) and large for gestational age infants (68.70 [54.78-79.09]ng/mL, p<0.01). The association between SGA and lower irisin remained significant in multivariate analysis independent of gestational age, maternal age, maternal BMI, and gestational diabetes (p=0.03). In singleton infants, irisin was also significantly negatively associated with maternal preeclampsia (p=0.01). CONCLUSIONS: Our results support the notion that irisin may have a physiologic role in neonates. We speculate that decreased levels of irisin in SGA infants may contribute to the development of catch-up growth and metabolic syndrome later in life.
BACKGROUND:Irisin is a novel myokine, secreted from skeletal muscle after exercise. Irisin mediates exercise-related energy expenditure by turning white adipose tissue (WAT) into brown adipose tissue (BAT). Thus, irisin is considered as a potential biomarker for obesity and metabolic syndrome. Infants born small for gestational age (SGA) have increased risk for metabolic syndrome. However, the physiologic role of irisin in neonates remains to be studied. OBJECTIVE: To evaluate the association of umbilical cord blood irisin levels with gestational age and birth weight categories in neonates. METHODS: A cross-sectional study of 341 newborns, from 26 to 41weeks' gestation. We collected umbilical cord blood and analyzed plasma for irisin by ELISA. RESULTS: Plasma irisin levels were positively correlated with gestational age (r=0.21, p<0.001), and birth weight Z-score (r=0.18, p<0.001). SGA infants had significantly lower irisin (median [interquartile range] 55.38 [46.56-65.72]ng/mL) compared to appropriate for gestational age infants (64.41 [53.87-76.76]ng/mL) and large for gestational age infants (68.70 [54.78-79.09]ng/mL, p<0.01). The association between SGA and lower irisin remained significant in multivariate analysis independent of gestational age, maternal age, maternal BMI, and gestational diabetes (p=0.03). In singleton infants, irisin was also significantly negatively associated with maternal preeclampsia (p=0.01). CONCLUSIONS: Our results support the notion that irisin may have a physiologic role in neonates. We speculate that decreased levels of irisin in SGA infants may contribute to the development of catch-up growth and metabolic syndrome later in life.
Authors: Miles J De Blasio; Kathryn L Gatford; I Caroline McMillen; Jeffrey S Robinson; Julie A Owens Journal: Endocrinology Date: 2006-11-16 Impact factor: 4.736
Authors: Mehmet Aytac Yuksel; Mahmut Oncul; Abdullah Tuten; Metehan Imamoglu; Abdullah Serdar Acikgoz; Mine Kucur; Riza Madazli Journal: Diabetes Res Clin Pract Date: 2014-01-03 Impact factor: 5.602
Authors: Joo Young Huh; Grigorios Panagiotou; Vassilis Mougios; Mary Brinkoetter; Maria T Vamvini; Benjamin E Schneider; Christos S Mantzoros Journal: Metabolism Date: 2012-09-25 Impact factor: 8.694
Authors: Jian-Jun Liu; Melvin D S Wong; Wan Ching Toy; Clara S H Tan; Sylvia Liu; Xiao Wei Ng; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim Journal: J Diabetes Complications Date: 2013-04-22 Impact factor: 2.852
Authors: Eileen I Chang; Paul J Rozance; Stephanie R Wesolowski; Leanna M Nguyen; Steven C Shaw; Robert A Sclafani; Kristen K Bjorkman; Angela K Peter; William Hay; Laura D Brown Journal: J Endocrinol Date: 2019-12-19 Impact factor: 4.286
Authors: Peck Yean Tan; Cheng Wei Chang; Kaibo Duan; Michael Poidinger; Kai Lyn Ng; Yap Seng Chong; Peter D Gluckman; Walter Stünkel Journal: PLoS One Date: 2016-09-15 Impact factor: 3.240